Introduction to Sars Cov 2 Nucleocapsid

Sentence Examples

Discover more insights into Sars Cov 2 Nucleocapsid

Keywords frequently search together with Sars Cov 2 Nucleocapsid

Narrow sentence examples with built-in keyword filters

Sars Cov 2 Nucleocapsid sentence examples within receptor binding domain

receptor binding domain

Antibodies against the SARS-CoV-2 nucleocapsid and the receptor binding domain of the S1 subunit of the spike protein were measured in all individuals at different time points.

Early antibody response in health-care professionals after two doses of SARS-CoV-2 mRNA vaccine (BNT162b2)

receptor binding domain

We found that 7-8 months after the infection their antibodies to SARS-CoV-2 Nucleocapsid (N) protein declined whereas we found no decrease in the antibodies to Spike receptor-binding domain (S-RBD) when compared to the findings at seropositivity identification.

Long-Term Elevated Inflammatory Protein Levels in Asymptomatic SARS-CoV-2 Infected Individuals

More receptor binding domain sentences More Sentences

Sars Cov 2 Nucleocapsid sentence examples within enzyme linked immunosorbent

enzyme linked immunosorbent

In this paper, we demonstrate the significant impact of dimerization of SARS-CoV-2 nucleocapsid protein on sensitivity of enzyme-linked immunosorbent assay (ELISA) based diagnostics of COVID-19.

Dimerization of SARS-CoV-2 nucleocapsid protein affects sensitivity of ELISA based diagnostics of COVID-19

enzyme linked immunosorbent

Here, we compared SARS-CoV-2 nucleocapsid antigen (N-Ag) testing using an enzyme-linked immunosorbent assay (ELISA) with SARS-CoV-2 RNA detection.

Parallel detection of SARS-CoV-2 RNA and nucleocapsid antigen in nasopharyngeal specimens from a COVID-19 patient screening cohort

More enzyme linked immunosorbent sentences More Sentences

Sars Cov 2 Nucleocapsid sentence examples within rapid affinity pair

rapid affinity pair

Here, we demonstrate the use of the rapid affinity pair identification via directed selection (RAPIDS) method to discover multiple affinity pairs for SARS-CoV-2 nucleocapsid protein (N-protein), a biomarker of COVID-19, from in vitro libraries in 10 weeks.

Developing a SARS-CoV-2 Antigen Test Using Engineered Affinity Proteins.

rapid affinity pair

Here, we demonstrate the use of the rapid affinity pair identification via directed selection (RAPIDS) method to discover multiple affinity pairs for SARS-CoV-2 nucleocapsid protein (N-protein), a biomarker of COVID-19, from in vitro libraries in 10 weeks.

Developing a SARS-CoV-2 antigen test using engineered affinity proteins

More rapid affinity pair sentences More Sentences

Learn more from Sars Cov 2 Nucleocapsid

Sars Cov 2 Nucleocapsid sentence examples within 2 spike protein

2 spike protein

The reactivity of IgG responses to SARS-CoV-2 nucleocapsid protein and IgM responses to SARS-CoV-2 spike protein could distinguish COVID-19 samples from non-COVID-19 and pre-pandemic samples.

Serological profiles of pan-coronavirus-specific responses in COVID-19 patients using a multiplexed electro-chemiluminescence-based testing platform

2 spike protein

The reactivity of IgG responses to SARS-CoV-2 nucleocapsid protein and IgM responses to SARS-CoV-2 spike protein could distinguish COVID-19 samples from non-COVID-19 and pre-pandemic samples.

Serological profiles of pan-coronavirus-specific responses in COVID-19 patients using a multiplexed electro-chemiluminescence-based testing platform

More 2 spike protein sentences More Sentences

Sars Cov 2 Nucleocapsid sentence examples within single molecule array

single molecule array

This study aimed to develop a highly sensitive SARS-CoV-2 nucleocapsid antigen assay using the single molecule array (Simoa) technology and compare it with real time RT-PCR as used in routine clinical practice with the ambition to achieve a comparative technical and clinical sensitivity.

Quantifying SARS-CoV-2 nucleocapsid antigen in oropharyngeal swabs using single molecule array technology

single molecule array

Background: This study aimed to develop a highly sensitive SARS-CoV-2 nucleocapsid antigen assay using the single molecule array (Simoa) technology and compare it with real time RT-PCR as used in routine clinical practice with the ambition to achieve a comparative technical and clinical sensitivity.

Quantifying SARS-Cov-2 Nucleocapsid Antigen in Oropharyngeal Swabs Using Single Molecule Array Technology

More single molecule array sentences More Sentences

Sars Cov 2 Nucleocapsid sentence examples within viral life cycle

viral life cycle

Very recently, by NMR spectroscopy, for the first time we have decoded that HCQ specifically binds both N-terminal domain (NTD) and C-terminal domain (CTD) of SARS-CoV-2 nucleocapsid (N) protein to inhibit their interactions with nucleic acids (NAs), as well as to disrupt its NA-induced liquid-liquid phase separation (LLPS) essential for the viral life cycle including the final package of gRNA and N protein into new virions.

Structural basis of anti-SARS-CoV-2 activity of hydroxychloroquine: specific binding to NTD/CTD and disruption of LLPS of N protein

viral life cycle

SARS-CoV-2 nucleocapsid (N) protein plays the essential roles in almost all key steps of the viral life cycle, thus representing a top drug target.

Structural basis of anti-SARS-CoV-2 activity of HCQ: specific binding to N protein to disrupt its interaction with nucleic acids and LLPS

More viral life cycle sentences More Sentences

More Sars Cov 2 Nucleocapsid sentence examples
10.1128/mSphere.00203-21

To this end, we identified a short epitope from the SARS-CoV-2 nucleocapsid protein and also a disease risk factor score based upon comorbidities and age.

Predicting COVID-19 Severity with a Specific Nucleocapsid Antibody plus Disease Risk Factor Score

More Sars Cov 2 Nucleocapsid sentence examples
10.1016/j.scib.2021.01.013

Here, we show that the SARS-CoV-2 nucleocapsid (N)protein, an RNA binding protein essential for viral production, interacted with Ras-GTPase-Activating protein SH3-domain-binding protein (G3BP) and disrupted SG assembly, both of which require intrinsically disordered region1 (IDR1) in N protein.

SARS-CoV-2 nucleocapsid protein phase separates with G3BPs to disassemble stress granules and facilitate viral production

More Sars Cov 2 Nucleocapsid sentence examples
10.1016/j.cmi.2021.05.004

Antibodies against the SARS-CoV-2 nucleocapsid and the receptor binding domain of the S1 subunit of the spike protein were measured in all individuals at different time points.

Early antibody response in health-care professionals after two doses of SARS-CoV-2 mRNA vaccine (BNT162b2)

More Sars Cov 2 Nucleocapsid sentence examples
10.1101/2021.06.01.446676

Examination of the placental samples with high virus content showed efficient SARS-CoV-2 infection, using RNA in situ hybridization to detect genomic and replicating viral RNA, and immunohistochemistry to detect SARS-CoV-2 nucleocapsid protein.

SARS-CoV-2 Infects Syncytiotrophoblast and Activates Inflammatory Responses in the Placenta

More Sars Cov 2 Nucleocapsid sentence examples
10.3389/fimmu.2021.709759

We found that 7-8 months after the infection their antibodies to SARS-CoV-2 Nucleocapsid (N) protein declined whereas we found no decrease in the antibodies to Spike receptor-binding domain (S-RBD) when compared to the findings at seropositivity identification.

Long-Term Elevated Inflammatory Protein Levels in Asymptomatic SARS-CoV-2 Infected Individuals

More Sars Cov 2 Nucleocapsid sentence examples
10.1101/2021.07.19.21260559

At entry, 50% evidenced production of anti-spike neutralizing antibodies; 50% had SARS-CoV-2 nucleocapsid plasma antigen levels [≥] 1,000 ng/L.

Clinical and Virological Response to a Neutralizing Monoclonal Antibody for Hospitalized Patients with COVID-19

More Sars Cov 2 Nucleocapsid sentence examples
10.3390/biology10060454

In this review, structural and dynamical aspects of the SARS-CoV-2 nucleocapsid protein (NCoV2), which should play a key role in a new drug development and in the interaction with RNA and other proteins are summarized.

Viewing SARS-CoV-2 Nucleocapsid Protein in Terms of Molecular Flexibility

More Sars Cov 2 Nucleocapsid sentence examples
10.3390/diagnostics11101838

The objective of this study is to develop a SH-SAW biosensor to detect the anti-SARS-CoV-2 nucleocapsid antibody.

A Novel Rapid Test to Detect Anti-SARS-CoV-2 N Protein IgG Based on Shear Horizontal Surface Acoustic Wave (SH-SAW)

More Sars Cov 2 Nucleocapsid sentence examples
10.1101/2021.03.02.21252362

We aim to understand the longitudinal humoral responses to SARS-CoV-2 nucleocapsid (N) protein and spike (S) protein and to evaluate their correlation to clinical symptoms among healthcare workers (HCW).

High Initial Titres of Anti-Spike Antibodies following SARS-CoV-2 Infection is Associated with Faster Decay Rates at Four Months Follow-Up

More Sars Cov 2 Nucleocapsid sentence examples
10.24075/BRSMU.2021.009

The aim of the work was to evaluate the use of the SARS-CoV-2 nucleocapsid antigen (N-Ag) and respective antibodies as diagnostic markers in pneumonia patients.

The importance of determining SARS-CoV-2 N-Ag serodiagnostics for the management of COVID-19 pneumonia in hospital settings

More Sars Cov 2 Nucleocapsid sentence examples
10.1021/acs.jproteome.1c00391

Although microbial identification in clinical microbiology using mass spectrometry is undertaken after culture, here we undertook a mass spectrometry-based approach that employed an enrichment step to capture and detect SARS-CoV-2 nucleocapsid protein directly from urine of COVID-19 patients without any culture.

Mass Spectrometric Analysis of Urine from COVID-19 Patients for Detection of SARS-CoV-2 Viral Antigen and to Study Host Response

More Sars Cov 2 Nucleocapsid sentence examples
10.1016/j.eclinm.2021.101172

Samples were tested for anti-SARS-CoV-2 nucleocapsid antibodies using the Roche e801 platform.

Community SARS-CoV-2 seroprevalence before and after the second wave of SARS-CoV-2 infection in Harare, Zimbabwe

More Sars Cov 2 Nucleocapsid sentence examples
10.1093/jmcb/mjab020

This is exactly what seems to happen with the condensation of SARS-CoV-2 nucleocapsid protein to favor the packaging of intact viral genomes, excluding viral subgenomic or host cellular RNAs.

Membraneless organelles restructured and built by pandemic viruses: HIV-1 and SARS-CoV-2

More Sars Cov 2 Nucleocapsid sentence examples
10.1021/acsomega.1c00253

We developed a highly sensitive and specific SARS-CoV-2 nucleocapsid protein-based ELISA method for the diagnosis and epidemiologic investigation of COVID-19 by SARS-CoV-2 IgM and IgG antibody detection.

Development of a Nucleocapsid Protein-Based ELISA for Detection of Human IgM and IgG Antibodies to SARS-CoV-2

More Sars Cov 2 Nucleocapsid sentence examples
10.21203/RS.3.RS-574216/V1

Antibodies against the SARS-CoV-2 nucleocapsid and the receptorbinding domain of the S1 subunit of the spike protein were measured in all individuals at different timepoints.

Antibody titers decline 3-month post-vaccination with BNT612b2

More Sars Cov 2 Nucleocapsid sentence examples
10.1186/s43141-021-00233-z

In this study, we analysed the SARS-CoV-2 nucleocapsid protein (N protein) with respect to the widely observed 28881-28883 GGG to AAC variant.

Analysing the impact of the two most common SARS-CoV-2 nucleocapsid protein variants on interactions with membrane protein in silico

More Sars Cov 2 Nucleocapsid sentence examples
10.1038/s41408-021-00546-9

Antibody (Ab) levels to the SARS-CoV-2 nucleocapsid (N) and spike (S) protein were measured at +1, +3, +6 months after nasal swabs became PCR-negative.

Production and persistence of specific antibodies in COVID-19 patients with hematologic malignancies: role of rituximab

More Sars Cov 2 Nucleocapsid sentence examples
10.1016/j.csbj.2021.06.016

This conjugate was shown to enrich recombinant SARS-CoV-2 nucleocapsid protein samples to about 6 folds.

Temperature responsive smart polymer for enabling affinity enrichment of current coronavirus (SARS-CoV-2) to improve its diagnostic sensitivity

More Sars Cov 2 Nucleocapsid sentence examples
10.1101/2021.03.12.21252149

We evaluated the durability of IgG responses specific to SARS-CoV-2 nucleocapsid (N), receptor binding domain (RBD), and spike (S) antigens in saliva up to 8 months after RT-PCR-confirmed COVID-19 using a multiplex salivary assay.

Durability of SARS-CoV-2-specific IgG responses in saliva for up to 8 months after infection

More Sars Cov 2 Nucleocapsid sentence examples
10.1016/j.clim.2021.108814

Two FDA-approved immunoassays against SARS-CoV-2 Nucleocapsid protein(NCP) and anti-spike-receptor binding domain(S-RBD) were used for sequential serological tests at different time points.

Longitudinal observation of antibody responses for 14 months after SARS-CoV-2 infection

More Sars Cov 2 Nucleocapsid sentence examples
10.3389/fimmu.2021.740260

In the left ventricular myocardium and lungs of COVID-19 patients, we found increased neuropilin-1 (NRP-1) RNA levels, which correlated strongly with the prevalence of pulmonary SARS-CoV-2 nucleocapsid.

Cardiac Fibrosis Is a Risk Factor for Severe COVID-19

More Sars Cov 2 Nucleocapsid sentence examples
10.1016/j.bios.2021.113669

In this article, we introduce the localized surface plasmon resonance (LSPR) principle on the aggregation of antigen-coated gold nanoparticles (GNPs) to detect SARS-CoV-2 Nucleocapsid (N) proteins.

Gold nanoparticle based plasmonic sensing for the detection of SARS-CoV-2 nucleocapsid proteins

More Sars Cov 2 Nucleocapsid sentence examples
10.12688/WELLCOMEOPENRES.16890.1

The study utilized a lateral flow rapid diagnostic test (RDT) which detected IgM and IgG antibodies against SARS-CoV-2 nucleocapsid protein.

Trends of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody prevalence in selected regions across Ghana

More Sars Cov 2 Nucleocapsid sentence examples
10.1111/dth.15076

A predominance of T CD4+ lymphocytes (Dako) over T CD8+ cells (Dako) was noticed (Figure 1C,D); immunostaining with anti-SARS-CoV-2 nucleocapsid protein antibody (Sino Biological) did not show any specific reactivity.

Cutaneous lymphocytic vasculitis after administration of COVID‐19 mRNA vaccine

More Sars Cov 2 Nucleocapsid sentence examples
10.1016/j.jneuroim.2021.577728

We herein report, by using confocal immunofluorescence, the colocalization of the SARS-CoV-2 nucleocapsid within neurons, astrocytes, oligodendrocytes and microglia in three deceased COVID-19 cases, of between 78 and 85 years of age at death.

The microglial NLRP3 inflammasome is involved in human SARS-CoV-2 cerebral pathogenicity: A report of three post-mortem cases

More Sars Cov 2 Nucleocapsid sentence examples
10.1038/s41421-021-00275-0

In this report, we found that the SARS-CoV-2 nucleocapsid protein (NP) impaired stress granule (SG) formation induced by viral RNA.

SARS-CoV-2 nucleocapsid protein impairs stress granule formation to promote viral replication

More Sars Cov 2 Nucleocapsid sentence examples
10.1016/j.snb.2021.130739

Here, we report an automatic label-free chemiluminescence immunoassay (CLIA) for rapid SARS-CoV-2 nucleocapsid protein (NP) detection with high sensitivity and throughput.

Automatic label-free immunoassay with high sensitivity for rapid detection of SARS-CoV-2 nucleocapsid protein based on chemiluminescent magnetic beads

More Sars Cov 2 Nucleocapsid sentence examples
10.1016/J.SNB.2021.130169

The sensor reported here is capable of detecting SARS-CoV-2 nucleocapsid gene amplicons at concentrations as low as 10 pg=µl (approximately 1:7 fM) and can detect nucleotides amplified after 10 PCR cycles.

Electrochemical sensing of SARS-CoV-2 amplicons with PCB electrodes

More Sars Cov 2 Nucleocapsid sentence examples
10.26434/chemrxiv.14442785.v1

Here, we demonstrate the use of the rapid affinity pair identification via directed selection (RAPIDS) method to discover multiple affinity pairs for SARS-CoV-2 nucleocapsid protein (N-protein), a biomarker of COVID-19, from in vitro libraries in 10 weeks.

Developing a SARS-CoV-2 Antigen Test Using Engineered Affinity Proteins.

More Sars Cov 2 Nucleocapsid sentence examples
10.1126/sciadv.abg7156

We also investigated whether the SARS-CoV-2 nucleocapsid protein (N) could increase vaccine efficacy.

Immunization with RBD-P2 and N protects against SARS-CoV-2 in nonhuman primates

More Sars Cov 2 Nucleocapsid sentence examples
10.1016/j.idcr.2021.e01291

Serological examination at the time of presentation revealed positive IgM and IgG antibodies against SARS-CoV-2 nucleocapsid protein.

Lofgren syndrome in close temporal association with mild COVID-19 – Case report

More Sars Cov 2 Nucleocapsid sentence examples
10.17116/patol2021830415

There were data of a morphological study, including a standard histological study, as well as immunohistochemical determination of the surface markers CD45, CD3, CD20, and CD68 cells of an inflammatory infiltrate and virus proteins (SARS-CoV-2 nucleocapsid protein and spike protein).

[Clinical and morphological characteristics of SARS-CoV-2-related myocarditis proven by the presence of viral RNA and proteins in myocardial tissue].

More Sars Cov 2 Nucleocapsid sentence examples
10.1101/2021.01.08.20248771

Recently, the presence of SARS-CoV-2 nucleocapsid antigen in serum samples of COVID-19 patients was published [Le Hingrat et al.

Detection of SARS-CoV-2 nucleocapsid antigen from serum can aid in timing of COVID-19 infection

More Sars Cov 2 Nucleocapsid sentence examples
10.12890/2021_002617

Conclusion SARS-CoV-2 nucleocapsid antibodies provide information about naturally acquired immunity.

The Meaning of SARS-CoV-2 Antibodies in a Patient with a Systemic Reaction to the mRNA-1273 SARS-CoV-2 Vaccine after Previous Natural Immunization

More Sars Cov 2 Nucleocapsid sentence examples
10.26434/CHEMRXIV.14471244.V1

Finally, we applied the exponential amplification methods in developing bioassays for detection of biomarkers including SARS-CoV-2 nucleocapsid protein, an antigen used in the diagnosis of COVID-19.

Exponential Amplification Using Photoredox Autocatalysis

More Sars Cov 2 Nucleocapsid sentence examples
10.1016/j.jcv.2021.104900

Testing of recombinant SARS-CoV-2 nucleocapsid with these variants demonstrated an approximate 1000-fold loss in sensitivity for the Quidel Sofia SARS Antigen FIA test associated with the D399N mutation, while the BinaxNOW and Quidel Quickvue SARS Antigen tests were unaffected by the mutation.

A SARS-CoV-2 Nucleocapsid Variant that Affects Antigen Test Performance

More Sars Cov 2 Nucleocapsid sentence examples
10.2139/SSRN.3909745

Comorbid lung disease and lower levels of initial IgG response to SARS-CoV-2 nucleocapsid antigen were associated with longer symptom duration.

Serum Biomarkers Predict Symptom Duration in Long Term COVID-19 Across a Diverse Population

More Sars Cov 2 Nucleocapsid sentence examples
10.1101/2021.04.25.21256067

The screening was performed using a strip-in-cassette lateral flow type Rapid Diagnostic Test (RDT) kit that simultaneously and separately detected IgM and IgG antibodies against SARS-CoV-2 nucleocapsid protein.

Trends of SARS-CoV-2 antibody prevalence in selected regions across Ghana

More Sars Cov 2 Nucleocapsid sentence examples
10.1101/2021.04.12.21255330

In a subsample of participants (n=82) at round 2, a second assay was performed that measured IgGs reactive to SARS-CoV-2 nucleocapsid protein (nucleocapsid-containing assay).

Identification of natural SARS-CoV-2 infection in seroprevalence studies among vaccinated populations

More Sars Cov 2 Nucleocapsid sentence examples
10.1101/2021.04.13.21255396

We described previously a fast, simple, and inexpensive Ni2+ magnetic bead immunoassay which allowed detection of human antibodies reacting against the SARS-CoV-2 nucleocapsid protein using a minimal amount of serum or blood.

Ultra-fast, high throughput and inexpensive detection of SARS-CoV-2 seroconversion

More Sars Cov 2 Nucleocapsid sentence examples
10.1016/j.jviromet.2021.114183

Study design Three monoclonal antibodies against SARS-CoV-2 nucleocapsid (N) protein were used to develop an antigen-antibody-based immunochromatographic kit to detect SARS-CoV-2.

Development of an immunochromatographic kit to detect severe acute respiratory syndrome coronavirus 2

More Sars Cov 2 Nucleocapsid sentence examples
10.12688/gatesopenres.13357.1

391) and in the rates of antibody seropositivity(IgM and IgG against SARS-CoV-2 nucleocapsid protein).

Asymptomatic COVID-19 in the elderly: dementia and viral clearance as risk factors for disease progression.

More Sars Cov 2 Nucleocapsid sentence examples
10.1515/cclm-2021-0569

The LIAISON® SARS-CoV-2 Ag test was evaluated for the quantification of SARS-CoV-2 nucleocapsid antigen in nasopharyngeal swabs by comparison to RT-PCR.

Performance evaluation of an automated SARS-CoV-2 Ag test for the diagnosis of COVID-19 infection on nasopharyngeal swabs

More Sars Cov 2 Nucleocapsid sentence examples
10.1016/j.envres.2021.111374

Quantitative RT-PCR N1 and N2 assays were used to measure SARS-CoV-2 nucleocapsid genes in wastewater.

Targeted wastewater surveillance of SARS-CoV-2 on a university campus for COVID-19 outbreak detection and mitigation

More Sars Cov 2 Nucleocapsid sentence examples
10.1101/2021.04.11.21255278

No anti-SARS-CoV-2 nucleocapsid (N) protein IgG antibody was detected in any of the participants during the study period, indicating that the anti-SARS-CoV-2 S1 IgG assay is specific for the mRNA vaccine induced antibodies.

A Single Drop of Fingerstick Blood for Quantitative Antibody Response Evaluation After SARS-CoV-2 Vaccination

More Sars Cov 2 Nucleocapsid sentence examples
10.1101/2021.05.05.21256527

Testing of recombinant SARS-CoV-2 nucleocapsid with these variants demonstrated an approximate 1000-fold loss in sensitivity for the Quidel Sofia SARS Antigen FIA test associated with the D399N mutation, while the BinaxNOW and Quidel Quickvue SARS Antigen tests were unaffected by the mutation.

A SARS-CoV-2 Nucleocapsid Variant that Affects Antigen Test Performance

More Sars Cov 2 Nucleocapsid sentence examples
10.1177/0963689720985453

But their anti-SARS-COV-2 nucleocapsid antibody showed a dynamic trend, consistent with the process of virus infection and clearance.

Are RNA-Based Tests Sufficient for COVID-19 Diagnosis? An Inspiration of Three Asymptomatic Cases

More Sars Cov 2 Nucleocapsid sentence examples
10.1101/2021.02.17.431755

Here we demonstrated that the SARS-CoV-2 nucleocapsid (N) protein dually regulated innate immune responses, i.

SARS-CoV-2 nucleocapsid protein dually regulates innate immune responses

More Sars Cov 2 Nucleocapsid sentence examples
10.3390/vaccines9050520

Methods: Using a macaque model of SARS-CoV-2 infection, we tested the efficacy of a peptide-based vaccine targeting MHC class I epitopes on the SARS-CoV-2 nucleocapsid protein.

A Synthetic Peptide CTL Vaccine Targeting Nucleocapsid Confers Protection from SARS-CoV-2 Challenge in Rhesus Macaques

More Sars Cov 2 Nucleocapsid sentence examples
10.1101/2021.05.14.21257100

Evaluation of detection limit was performed with purified SARS-CoV-2 nucleocapsid protein and titrated live SARS-CoV-2 virus and compared to Abbott Panbio COVID-19 Ag Rapid Test (Panbio) designed for nasopharyngeal samples.

Evaluation of SARS-CoV-2 rapid antigen diagnostic tests for saliva samples

More Sars Cov 2 Nucleocapsid sentence examples
10.1128/JCM.03077-20

Currently available rapid diagnostic tests (RDTs) for SARS-CoV-2 nucleocapsid antigens (Ag) have sensitivity well below PCR.

Correlation of SARS-CoV-2 Nucleocapsid Antigen and RNA Concentrations in Nasopharyngeal Samples from Children and Adults Using an Ultrasensitive and Quantitative Antigen Assay

More Sars Cov 2 Nucleocapsid sentence examples
10.1016/j.ebiom.2021.103480

In this article of EBioMedicine, Santosh Renuse and colleagues1 show the relevance of combining immunoaffinity capture with targeted mass spectrometry measurement to detect SARS-CoV-2 nucleocapsid proteins in nasopharyngeal swab samples.

Unleashing immuno-mass spectrometry superpowers to detect SARS-CoV-2

More Sars Cov 2 Nucleocapsid sentence examples
10.1016/j.ebiom.2021.103539

Furthermore, T cell responses were stronger in convalescents and particularly strong against the SARS-CoV-2 nucleocapsid protein.

B and T cell response to SARS-CoV-2 vaccination in health care professionals with and without previous COVID-19

More Sars Cov 2 Nucleocapsid sentence examples
10.1016/j.jcvp.2021.100030

We evaluated the analytical and clinical performance of the Genalyte Maverick SARS-CoV-2 Multi-Antigen Serology Panel compared to the Roche Elecsys Anti-SARS-CoV-2 nucleocapsid (NC) qualitative immunoassay, using well characterized clinical serum samples.

Evaluation of the genalyte maverick SARS-CoV-2 multi-antigen serology panel

More Sars Cov 2 Nucleocapsid sentence examples
10.1016/j.virol.2021.01.003

The SARS-CoV-2 nucleocapsid protein is critical for viral replication, integral to viral particle assembly, and a major diagnostic marker for infection and immune protection.

Development of a SARS-CoV-2 nucleocapsid specific monoclonal antibody

More Sars Cov 2 Nucleocapsid sentence examples
10.1093/clinchem/hvab216

Background Detection of SARS-CoV-2 nucleocapsid antigen in blood has been described, but the diagnostic and prognostic role of antigenemia is not well understood.

SARS-CoV-2 Nucleocapsid Plasma Antigen for Diagnosis and Monitoring of COVID-19

More Sars Cov 2 Nucleocapsid sentence examples
10.1186/s13018-021-02563-7

4% and 4% for IgG antibodies specific for SARS-CoV-2 nucleocapsid and spike proteins, respectively.

COVID-19 (SARS-CoV-2) lymphocyte responses are associated with inflammatory biomarkers in total joint replacement surgery candidates pre-operatively

More Sars Cov 2 Nucleocapsid sentence examples
10.1101/2021.02.22.432218

In infected ACE2-iPS cells, the expression of SARS-CoV-2 nucleocapsid protein, the budding of viral particles, the production of progeny virus, double membrane spherules, and double-membrane vesicles were confirmed.

Modeling SARS-CoV-2 infection and its individual differences with ACE2-expressing human iPS cells

More Sars Cov 2 Nucleocapsid sentence examples
10.3390/v13081648

In a longitudinal cohort study conducted in 26 model regions of Russia, distributed across all FDs, we investigated the distribution and cumulative proportions of individuals with antibodies (Abs) to the SARS-CoV-2 nucleocapsid antigen (Ag), in the period from June to December 2020, using a three-phase monitoring process.

SARS-CoV-2 Seroprevalence Structure of the Russian Population during the COVID-19 Pandemic

More Sars Cov 2 Nucleocapsid sentence examples
10.1080/14760584.2021.1977630

Study subjects were categorized into two groups, convalescent and uninfected, based on prior infection history and SARS-CoV-2 nucleocapsid-IgG profiles.

Antibody response to the first dose of AZD1222 vaccine in COVID-19 convalescent and uninfected individuals in Bangladesh

More Sars Cov 2 Nucleocapsid sentence examples
10.1021/jacs.1c04236

Finally, we applied the exponential amplification methods in developing bioassays for detection of biomarkers including SARS-CoV-2 nucleocapsid protein, an antigen used in the diagnosis of COVID-19.

Exponential Amplification Using Photoredox Autocatalysis.

More Sars Cov 2 Nucleocapsid sentence examples
10.3390/ijerph18010323

A chemiluminescent microparticle immunoassay (CMIA) will be used for the qualitative detection of IgG antibodies against SARS-CoV-2 nucleocapsid protein.

Eastern Cape Healthcare Workers Acquisition of SARS-CoV-2 (ECHAS): Cross-Sectional (Nested Cohort) Study Protocol

More Sars Cov 2 Nucleocapsid sentence examples
10.1089/vim.2021.0061

We investigated IgM and IgG responses against SARS-CoV-2 nucleocapsid (N) and receptor-binding domain (RBD) of spike protein in two groups of recovered and deceased COVID-19 patients.

Differential Antibody Response to SARS-CoV-2 Antigens in Recovered and Deceased Iranian COVID-19 Patients.

More Sars Cov 2 Nucleocapsid sentence examples
10.1101/2021.07.12.21260379

We tested pre-pandemic (2015-2019) plasma samples from 148 Vietnamese children, and 100 Vietnamese adults at high risk of zoonotic infections, for antibodies against SARS-CoV-2 nucleocapsid and spike proteins.

Absence of SARS-CoV-2 antibodies in pre-pandemic plasma from children and adults in Vietnam

More Sars Cov 2 Nucleocapsid sentence examples
10.1515/cclm-2021-0744

Consequently, they showed undetectable baseline anti-SARS-CoV-2 immunoglobulin (Ig) levels before CP treatment according to Elecsys® SARS-CoV-2 nucleocapsid-and S1-RBD-specific total Ig tests (Roche, Mannheim, Germany).

Laboratory follow-up of convalescent plasma treatment in B-cell depleted patients with COVID-19 pneumonia

More Sars Cov 2 Nucleocapsid sentence examples
10.1016/j.pep.2021.105908

Virus infection always induce high antibody titer against SARS-CoV-2 nucleocapsid protein (N protein), which can be used to detect COVID-19 at both infected and convalescent patients.

Expression and purification of recombinant SARS-CoV-2 nucleocapsid protein in inclusion bodies and its application in serological detection

More Sars Cov 2 Nucleocapsid sentence examples
10.1101/2021.07.18.21260555

9363 samples were collected from 30 wards distributed over 6 zones of Hyderabad and tested for antibodies against SARS-CoV-2 nucleocapsid antigen.

SARS-CoV-2 seroprevalence in the city of Hyderabad, India in early 2021

More Sars Cov 2 Nucleocapsid sentence examples
10.1016/S2214-109X(21)00355-7

We report anti-SARS-CoV-2 nucleocapsid IgG antibody seroconversion rates and associated risk factors in Manaus residents before the second wave of the epidemic in Brazil.

High anti-SARS-CoV-2 antibody seroconversion rates before the second wave in Manaus, Brazil, and the protective effect of social behaviour measures: results from the prospective DETECTCoV-19 cohort

More Sars Cov 2 Nucleocapsid sentence examples
10.3390/v13091816

Results: Immunohistochemistry (IHC) of SARS-CoV-2 nucleocapsid proteins and subsequent correlative microscopy undoubtedly proved the presence of SARS-CoV-2 virions in the analysed human nasopharyngeal tissue.

Just Seeing Is Not Enough for Believing: Immunolabelling as Indisputable Proof of SARS-CoV-2 Virions in Infected Tissue

More Sars Cov 2 Nucleocapsid sentence examples
10.3390/v13050796

We developed and clinically evaluated an immunochromatographic immunoassay, GenBody™ COVAG025, for the rapid detection of SARS-CoV-2 nucleocapsid (NP) antigen in two different clinical studies.

Development and Clinical Evaluation of an Immunochromatography-Based Rapid Antigen Test (GenBody™ COVAG025) for COVID-19 Diagnosis

More Sars Cov 2 Nucleocapsid sentence examples
10.1556/650.2021.32363

METHOD After vaccination, the infection rate, adverse events and the kinetics of anti-SARS-CoV-2 spike (S) protein and anti-SARS-CoV-2 nucleocapsid (N) protein antibodies were evaluated.

Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in healthcare workers

More Sars Cov 2 Nucleocapsid sentence examples
10.1038/s41598-021-82428-5

We measured the titers of SARS-CoV-2 IgM and IgG in sera from 105 subjects, including 26 symptomatic COVID-19 patients, using chemiluminescent immunoassay (CLIA) methods utilizing magnetic beads coated with SARS-CoV-2 nucleocapsid protein and spike protein.

Time course of the sensitivity and specificity of anti-SARS-CoV-2 IgM and IgG antibodies for symptomatic COVID-19 in Japan

More Sars Cov 2 Nucleocapsid sentence examples
10.21203/RS.3.RS-618366/V1

In this study, we aimed to assess the dynamics of IgG antibody titers in recovered COVID-19 patients over 14 months after mild and moderately severe infection using two FDA-approved immunoassays against SARS-CoV-2 Nucleocapsid protein (NCP)and anti-spike-receptor binding domain (S-RBD) through sequential serological tests at different time points.

Longitudinal observation of antibody responses after SARS-CoV-2 infection at 14 months

More Sars Cov 2 Nucleocapsid sentence examples
10.4049/immunohorizons.2100011

We measured IgA, IgG, and/or IgM against SARS-CoV-2 nucleocapsid (N), spike domain 1 (S1), S1–receptor binding domain (RBD) and S1–N-terminal domain.

One-Stop Serum Assay Identifies COVID-19 Disease Severity and Vaccination Responses

More Sars Cov 2 Nucleocapsid sentence examples
10.1101/2021.04.19.440086

We identify 269 peptide-based interactions for 18 coronaviruses including a specific interaction between the human G3BP1/2 proteins and an ΦxFG peptide motif in the SARS-CoV-2 nucleocapsid (N) protein.

Large scale discovery of coronavirus-host factor protein interaction motifs reveals SARS-CoV-2 specific mechanisms and vulnerabilities

More Sars Cov 2 Nucleocapsid sentence examples
10.3201/eid2705.204055

Furthermore, our findings exclude SARS-CoV-2 nucleocapsid protein as an antigen for serologic screening of cat and dog samples.

Serologic Screening of Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Cats and Dogs during First Coronavirus Disease Wave, the Netherlands

More Sars Cov 2 Nucleocapsid sentence examples
10.1101/2021.05.23.445305

In this paper, we demonstrate the significant impact of dimerization of SARS-CoV-2 nucleocapsid protein on sensitivity of enzyme-linked immunosorbent assay (ELISA) based diagnostics of COVID-19.

Dimerization of SARS-CoV-2 nucleocapsid protein affects sensitivity of ELISA based diagnostics of COVID-19

More Sars Cov 2 Nucleocapsid sentence examples
10.1101/2021.05.21.445201

A previous report demonstrated the strong association between the presence of antibodies binding to an epitope region from SARS-CoV-2 nucleocapsid, termed Ep9, and COVID-19 disease severity.

Evidence for Deleterious Antigenic Imprinting in SARS-CoV-2 Immune Response

More Sars Cov 2 Nucleocapsid sentence examples
10.1021/acssensors.0c02544

Recombinant 6xHis-tagged SARS-CoV-2 Nucleocapsid protein was mobilized on the surface of Ni2+ magnetic beads and challenged with serum or blood samples obtained from controls or COVID-19 cases.

Magnetic Bead-Based Immunoassay Allows Rapid, Inexpensive, and Quantitative Detection of Human SARS-CoV-2 Antibodies

More Sars Cov 2 Nucleocapsid sentence examples
10.1371/journal.pone.0252628

The reactivity of IgG responses to SARS-CoV-2 nucleocapsid protein and IgM responses to SARS-CoV-2 spike protein could distinguish COVID-19 samples from non-COVID-19 and pre-pandemic samples.

Serological profiles of pan-coronavirus-specific responses in COVID-19 patients using a multiplexed electro-chemiluminescence-based testing platform

More Sars Cov 2 Nucleocapsid sentence examples
10.1016/j.bios.2021.113647

Rapid detection of SARS-CoV-2 nucleocapsid (N) and spike (S1) receptor binding domain (RBD) proteins was first demonstrated at a clinically relevant concentration down to 1 ng mL-1 (33 pM) by real-time monitoring of nanomechanical signal induced by antibody-antigen interaction.

Highly sensitive and ultra-rapid antigen-based detection of SARS-CoV-2 using nanomechanical sensor platform

More Sars Cov 2 Nucleocapsid sentence examples
10.1101/2021.05.06.21256706

We show that two consecutive mutations (R203K/G204R) in the SARS-CoV-2 nucleocapsid (N) protein are associated with higher viral loads in COVID-19 patients.

Saudi Arabian SARS-CoV-2 genomes implicate a mutant Nucleocapsid protein in modulating host interactions and increased viral load in COVID-19 patients

More Sars Cov 2 Nucleocapsid sentence examples
10.5858/arpa.2020-0793-SA

Sixty-four of the placentas from the SARS-CoV-2-positive group underwent immunohistochemical staining for SARS-CoV-2 nucleocapsid protein.

Histologic and Immunohistochemical Evaluation of 65 Placentas from Women with Polymerase Chain Reaction-proven Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection.

More Sars Cov 2 Nucleocapsid sentence examples
10.1016/j.jmb.2021.167108

To begin addressing the SARS-CoV-2 nucleocapsid protein interactions with both RNA and the host cell along with its dynamic behavior, we have specifically focused on the folded N-terminal domain (NTD) and its flanking regions using nuclear magnetic resonance solution studies.

The Inherent Dynamics and Interaction Sites of the SARS-CoV-2 Nucleocapsid N-Terminal Region

More Sars Cov 2 Nucleocapsid sentence examples
10.1093/ecco-jcc/jjab153

Methods Seroprevalence and the magnitude of SARS-CoV-2 nucleocapsid antibody responses were measured in surplus serum from 11 422 (53.

Adalimumab and Infliximab Impair SARS-CoV-2 Antibody Responses: Results from a Therapeutic Drug Monitoring Study in 11 422 Biologic-Treated Patients

More Sars Cov 2 Nucleocapsid sentence examples
10.26434/chemrxiv.14442785

Here, we demonstrate the use of the rapid affinity pair identification via directed selection (RAPIDS) method to discover multiple affinity pairs for SARS-CoV-2 nucleocapsid protein (N-protein), a biomarker of COVID-19, from in vitro libraries in 10 weeks.

Developing a SARS-CoV-2 antigen test using engineered affinity proteins

More Sars Cov 2 Nucleocapsid sentence examples
10.1021/acssensors.0c02561

The objective of this work was to develop a simple immunosensor for rapid and high sensitivity measurements of SARS-CoV-2 nucleocapsid protein in serum.

Microfluidic Magneto Immunosensor for Rapid, High Sensitivity Measurements of SARS-CoV-2 Nucleocapsid Protein in Serum

More Sars Cov 2 Nucleocapsid sentence examples
10.3390/pathogens10081039

The SARS-CoV-2 nucleocapsid protein (N) binds a single-stranded viral RNA genome to form a helical ribonucleoprotein complex that is packaged into virion particles.

Recombinant SARS-CoV-2 Nucleocapsid Protein: Expression, Purification, and Its Biochemical Characterization and Utility in Serological Assay Development to Assess Immunological Responses to SARS-CoV-2 Infection

Learn more from Sars Cov 2 Nucleocapsid

Keywords related to Sars

Sars Cov 2 Nucleocapsid
Encyclopedia

What is/are Sars Cov 2 Nucleocapsid?

Sars Cov 2 Nucleocapsid - To this end, we identified a short epitope from the SARS-CoV-2 nucleocapsid protein and also a disease risk factor score based upon comorbidities and age. [1] Here, we show that the SARS-CoV-2 nucleocapsid (N)protein, an RNA binding protein essential for viral production, interacted with Ras-GTPase-Activating protein SH3-domain-binding protein (G3BP) and disrupted SG assembly, both of which require intrinsically disordered region1 (IDR1) in N protein. [2] Antibodies against the SARS-CoV-2 nucleocapsid and the receptor binding domain of the S1 subunit of the spike protein were measured in all individuals at different time points. [3] Examination of the placental samples with high virus content showed efficient SARS-CoV-2 infection, using RNA in situ hybridization to detect genomic and replicating viral RNA, and immunohistochemistry to detect SARS-CoV-2 nucleocapsid protein. [4] We found that 7-8 months after the infection their antibodies to SARS-CoV-2 Nucleocapsid (N) protein declined whereas we found no decrease in the antibodies to Spike receptor-binding domain (S-RBD) when compared to the findings at seropositivity identification. [5] At entry, 50% evidenced production of anti-spike neutralizing antibodies; 50% had SARS-CoV-2 nucleocapsid plasma antigen levels [≥] 1,000 ng/L. [6] In this review, structural and dynamical aspects of the SARS-CoV-2 nucleocapsid protein (NCoV2), which should play a key role in a new drug development and in the interaction with RNA and other proteins are summarized. [7] The objective of this study is to develop a SH-SAW biosensor to detect the anti-SARS-CoV-2 nucleocapsid antibody. [8] We aim to understand the longitudinal humoral responses to SARS-CoV-2 nucleocapsid (N) protein and spike (S) protein and to evaluate their correlation to clinical symptoms among healthcare workers (HCW). [9] The aim of the work was to evaluate the use of the SARS-CoV-2 nucleocapsid antigen (N-Ag) and respective antibodies as diagnostic markers in pneumonia patients. [10] Although microbial identification in clinical microbiology using mass spectrometry is undertaken after culture, here we undertook a mass spectrometry-based approach that employed an enrichment step to capture and detect SARS-CoV-2 nucleocapsid protein directly from urine of COVID-19 patients without any culture. [11] Samples were tested for anti-SARS-CoV-2 nucleocapsid antibodies using the Roche e801 platform. [12] This is exactly what seems to happen with the condensation of SARS-CoV-2 nucleocapsid protein to favor the packaging of intact viral genomes, excluding viral subgenomic or host cellular RNAs. [13] We developed a highly sensitive and specific SARS-CoV-2 nucleocapsid protein-based ELISA method for the diagnosis and epidemiologic investigation of COVID-19 by SARS-CoV-2 IgM and IgG antibody detection. [14] Antibodies against the SARS-CoV-2 nucleocapsid and the receptorbinding domain of the S1 subunit of the spike protein were measured in all individuals at different timepoints. [15] In this study, we analysed the SARS-CoV-2 nucleocapsid protein (N protein) with respect to the widely observed 28881-28883 GGG to AAC variant. [16] Antibody (Ab) levels to the SARS-CoV-2 nucleocapsid (N) and spike (S) protein were measured at +1, +3, +6 months after nasal swabs became PCR-negative. [17] This conjugate was shown to enrich recombinant SARS-CoV-2 nucleocapsid protein samples to about 6 folds. [18] We evaluated the durability of IgG responses specific to SARS-CoV-2 nucleocapsid (N), receptor binding domain (RBD), and spike (S) antigens in saliva up to 8 months after RT-PCR-confirmed COVID-19 using a multiplex salivary assay. [19] Two FDA-approved immunoassays against SARS-CoV-2 Nucleocapsid protein(NCP) and anti-spike-receptor binding domain(S-RBD) were used for sequential serological tests at different time points. [20] In the left ventricular myocardium and lungs of COVID-19 patients, we found increased neuropilin-1 (NRP-1) RNA levels, which correlated strongly with the prevalence of pulmonary SARS-CoV-2 nucleocapsid. [21] In this article, we introduce the localized surface plasmon resonance (LSPR) principle on the aggregation of antigen-coated gold nanoparticles (GNPs) to detect SARS-CoV-2 Nucleocapsid (N) proteins. [22] The study utilized a lateral flow rapid diagnostic test (RDT) which detected IgM and IgG antibodies against SARS-CoV-2 nucleocapsid protein. [23] A predominance of T CD4+ lymphocytes (Dako) over T CD8+ cells (Dako) was noticed (Figure 1C,D); immunostaining with anti-SARS-CoV-2 nucleocapsid protein antibody (Sino Biological) did not show any specific reactivity. [24] We herein report, by using confocal immunofluorescence, the colocalization of the SARS-CoV-2 nucleocapsid within neurons, astrocytes, oligodendrocytes and microglia in three deceased COVID-19 cases, of between 78 and 85 years of age at death. [25] In this report, we found that the SARS-CoV-2 nucleocapsid protein (NP) impaired stress granule (SG) formation induced by viral RNA. [26] Here, we report an automatic label-free chemiluminescence immunoassay (CLIA) for rapid SARS-CoV-2 nucleocapsid protein (NP) detection with high sensitivity and throughput. [27] The sensor reported here is capable of detecting SARS-CoV-2 nucleocapsid gene amplicons at concentrations as low as 10 pg=µl (approximately 1:7 fM) and can detect nucleotides amplified after 10 PCR cycles. [28] Here, we demonstrate the use of the rapid affinity pair identification via directed selection (RAPIDS) method to discover multiple affinity pairs for SARS-CoV-2 nucleocapsid protein (N-protein), a biomarker of COVID-19, from in vitro libraries in 10 weeks. [29] We also investigated whether the SARS-CoV-2 nucleocapsid protein (N) could increase vaccine efficacy. [30] Serological examination at the time of presentation revealed positive IgM and IgG antibodies against SARS-CoV-2 nucleocapsid protein. [31] There were data of a morphological study, including a standard histological study, as well as immunohistochemical determination of the surface markers CD45, CD3, CD20, and CD68 cells of an inflammatory infiltrate and virus proteins (SARS-CoV-2 nucleocapsid protein and spike protein). [32] Recently, the presence of SARS-CoV-2 nucleocapsid antigen in serum samples of COVID-19 patients was published [Le Hingrat et al. [33] Conclusion SARS-CoV-2 nucleocapsid antibodies provide information about naturally acquired immunity. [34] Finally, we applied the exponential amplification methods in developing bioassays for detection of biomarkers including SARS-CoV-2 nucleocapsid protein, an antigen used in the diagnosis of COVID-19. [35] Testing of recombinant SARS-CoV-2 nucleocapsid with these variants demonstrated an approximate 1000-fold loss in sensitivity for the Quidel Sofia SARS Antigen FIA test associated with the D399N mutation, while the BinaxNOW and Quidel Quickvue SARS Antigen tests were unaffected by the mutation. [36] Comorbid lung disease and lower levels of initial IgG response to SARS-CoV-2 nucleocapsid antigen were associated with longer symptom duration. [37] The screening was performed using a strip-in-cassette lateral flow type Rapid Diagnostic Test (RDT) kit that simultaneously and separately detected IgM and IgG antibodies against SARS-CoV-2 nucleocapsid protein. [38] In a subsample of participants (n=82) at round 2, a second assay was performed that measured IgGs reactive to SARS-CoV-2 nucleocapsid protein (nucleocapsid-containing assay). [39] We described previously a fast, simple, and inexpensive Ni2+ magnetic bead immunoassay which allowed detection of human antibodies reacting against the SARS-CoV-2 nucleocapsid protein using a minimal amount of serum or blood. [40] Study design Three monoclonal antibodies against SARS-CoV-2 nucleocapsid (N) protein were used to develop an antigen-antibody-based immunochromatographic kit to detect SARS-CoV-2. [41] 391) and in the rates of antibody seropositivity(IgM and IgG against SARS-CoV-2 nucleocapsid protein). [42] The LIAISON® SARS-CoV-2 Ag test was evaluated for the quantification of SARS-CoV-2 nucleocapsid antigen in nasopharyngeal swabs by comparison to RT-PCR. [43] Quantitative RT-PCR N1 and N2 assays were used to measure SARS-CoV-2 nucleocapsid genes in wastewater. [44] No anti-SARS-CoV-2 nucleocapsid (N) protein IgG antibody was detected in any of the participants during the study period, indicating that the anti-SARS-CoV-2 S1 IgG assay is specific for the mRNA vaccine induced antibodies. [45] Testing of recombinant SARS-CoV-2 nucleocapsid with these variants demonstrated an approximate 1000-fold loss in sensitivity for the Quidel Sofia SARS Antigen FIA test associated with the D399N mutation, while the BinaxNOW and Quidel Quickvue SARS Antigen tests were unaffected by the mutation. [46] But their anti-SARS-COV-2 nucleocapsid antibody showed a dynamic trend, consistent with the process of virus infection and clearance. [47] Here we demonstrated that the SARS-CoV-2 nucleocapsid (N) protein dually regulated innate immune responses, i. [48] Methods: Using a macaque model of SARS-CoV-2 infection, we tested the efficacy of a peptide-based vaccine targeting MHC class I epitopes on the SARS-CoV-2 nucleocapsid protein. [49] Evaluation of detection limit was performed with purified SARS-CoV-2 nucleocapsid protein and titrated live SARS-CoV-2 virus and compared to Abbott Panbio COVID-19 Ag Rapid Test (Panbio) designed for nasopharyngeal samples. [50]

receptor binding domain

Antibodies against the SARS-CoV-2 nucleocapsid and the receptor binding domain of the S1 subunit of the spike protein were measured in all individuals at different time points. [1] We found that 7-8 months after the infection their antibodies to SARS-CoV-2 Nucleocapsid (N) protein declined whereas we found no decrease in the antibodies to Spike receptor-binding domain (S-RBD) when compared to the findings at seropositivity identification. [2] We evaluated the durability of IgG responses specific to SARS-CoV-2 nucleocapsid (N), receptor binding domain (RBD), and spike (S) antigens in saliva up to 8 months after RT-PCR-confirmed COVID-19 using a multiplex salivary assay. [3] Two FDA-approved immunoassays against SARS-CoV-2 Nucleocapsid protein(NCP) and anti-spike-receptor binding domain(S-RBD) were used for sequential serological tests at different time points. [4] We investigated IgM and IgG responses against SARS-CoV-2 nucleocapsid (N) and receptor-binding domain (RBD) of spike protein in two groups of recovered and deceased COVID-19 patients. [5] In this study, we aimed to assess the dynamics of IgG antibody titers in recovered COVID-19 patients over 14 months after mild and moderately severe infection using two FDA-approved immunoassays against SARS-CoV-2 Nucleocapsid protein (NCP)and anti-spike-receptor binding domain (S-RBD) through sequential serological tests at different time points. [6] Rapid detection of SARS-CoV-2 nucleocapsid (N) and spike (S1) receptor binding domain (RBD) proteins was first demonstrated at a clinically relevant concentration down to 1 ng mL-1 (33 pM) by real-time monitoring of nanomechanical signal induced by antibody-antigen interaction. [7] Antibodies against the SARS-CoV-2 nucleocapsid and the receptor binding domain of the S1 subunit of the spike protein were measured in all individuals at different time points. [8] Antibody tests against the SARS-CoV-2 nucleocapsid and receptor-binding domain (RBD) of the spike protein using the antiSARS-CoV-2 S enzyme immunoassay (Roche Elecsys) were both negative on May 31, 2021. [9] Total antibody responses to SARS-CoV-2 nucleocapsid (N) and spike protein receptor binding domain (S/RBD) were assessed using commercial immunoassays. [10] Total antibody testing (Anti-SARS-CoV-2 nucleocapsid and Anti-SARS-CoV-2 spike) were complemented by receptor binding domain indirect ELISA and neutralising antibody assays. [11] While Ro-pan-Ig only detects antibodies against the SARS-CoV-2 nucleocapsid antigen, Eu-IgG exclusively binds Abs to the receptor binding domain (RBD). [12]

enzyme linked immunosorbent

In this paper, we demonstrate the significant impact of dimerization of SARS-CoV-2 nucleocapsid protein on sensitivity of enzyme-linked immunosorbent assay (ELISA) based diagnostics of COVID-19. [1] Here, we compared SARS-CoV-2 nucleocapsid antigen (N-Ag) testing using an enzyme-linked immunosorbent assay (ELISA) with SARS-CoV-2 RNA detection. [2] The purpose of this study was to characterize the diagnostic performance of a newly developed enzyme-linked immunosorbent assay (ELISA) for detection of SARS-CoV-2 nucleocapsid protein (NP) in blood. [3] Four semiquantitative enzyme-linked immunosorbent assays (ELISAs) (Euroimmun anti-SARS-CoV-2 nucleocapsid protein [NCP] immunoglobulin G [IgG], Euroimmun spike SARS-CoV-2 IgG, Mologic Omega COVID-19 IgG, Bio-Rad Platelia SARS-CoV-2 Total Ab) and one chemiluminescent microparticle immunoassay (Abbott Architect SARS-CoV-2 IgG) were evaluated. [4] We have developed enzyme-linked immunosorbent assays (ELISAs) using recombinant SARS-CoV-2 nucleocapsid (N) protein and the receptor-binding-domain (RBD) of the spike protein, and the SARS-CoV-2 spike-pseudotyped vesicular stomatitis virus (VSV)-based neutralization assay to screen serum samples of 239 pet cats and 510 pet dogs in Minnesota in the early phase of the COVID-19 pandemic from mid-April to early June 2020 for evidence of SARS-CoV-2 exposures. [5] The method provided for the formation of a group of volunteers in a model federative entity, including children aged 1–17 years, in which the presence of antibodies to the SARS-CoV-2 nucleocapsid was determined in venous blood plasma by the enzyme-linked immunosorbent assay (ELISA). [6] Here, we developed a SARS-CoV-2 nucleocapsid protein-based competitive enzyme-linked immunosorbent assay (cELISA) for serodiagnosis of COVID-19 which can theoretically be used in virtually all kinds of animals. [7]

rapid affinity pair

Here, we demonstrate the use of the rapid affinity pair identification via directed selection (RAPIDS) method to discover multiple affinity pairs for SARS-CoV-2 nucleocapsid protein (N-protein), a biomarker of COVID-19, from in vitro libraries in 10 weeks. [1] Here, we demonstrate the use of the rapid affinity pair identification via directed selection (RAPIDS) method to discover multiple affinity pairs for SARS-CoV-2 nucleocapsid protein (N-protein), a biomarker of COVID-19, from in vitro libraries in 10 weeks. [2] Here, we demonstrate the use of the rapid affinity pair identification via directed selection (RAPIDS) method to discover multiple affinity pairs for SARS-CoV-2 nucleocapsid protein (N-protein), a biomarker of COVID-19, from in vitro libraries in 10 weeks. [3]

2 spike protein

The reactivity of IgG responses to SARS-CoV-2 nucleocapsid protein and IgM responses to SARS-CoV-2 spike protein could distinguish COVID-19 samples from non-COVID-19 and pre-pandemic samples. [1] The reactivity of IgG responses to SARS-CoV-2 nucleocapsid protein and IgM responses to SARS-CoV-2 spike protein could distinguish COVID-19 samples from non-COVID-19 and pre-pandemic samples. [2] The TEXAS Coronavirus Antibody REsponse Survey (CARES) is a statewide seroprevalence program which utilizes the Roche S-test to detect antibodies to the SARS-CoV-2 spike protein and the Roche N-test to detect antibodies to the SARS-CoV-2 nucleocapsid protein, to monitor the combined impact of prior infection and the COVID-19 vaccine. [3]

single molecule array

This study aimed to develop a highly sensitive SARS-CoV-2 nucleocapsid antigen assay using the single molecule array (Simoa) technology and compare it with real time RT-PCR as used in routine clinical practice with the ambition to achieve a comparative technical and clinical sensitivity. [1] Background: This study aimed to develop a highly sensitive SARS-CoV-2 nucleocapsid antigen assay using the single molecule array (Simoa) technology and compare it with real time RT-PCR as used in routine clinical practice with the ambition to achieve a comparative technical and clinical sensitivity. [2] Here we report a highly sensitive single molecule array (Simoa) immunoassay in development for detection of SARS-CoV-2 nucleocapsid protein (N-protein) in venous and capillary blood and saliva. [3]

viral life cycle

Very recently, by NMR spectroscopy, for the first time we have decoded that HCQ specifically binds both N-terminal domain (NTD) and C-terminal domain (CTD) of SARS-CoV-2 nucleocapsid (N) protein to inhibit their interactions with nucleic acids (NAs), as well as to disrupt its NA-induced liquid-liquid phase separation (LLPS) essential for the viral life cycle including the final package of gRNA and N protein into new virions. [1] SARS-CoV-2 nucleocapsid (N) protein plays the essential roles in almost all key steps of the viral life cycle, thus representing a top drug target. [2] SARS-CoV-2 nucleocapsid (N) protein plays the essential roles in almost all key steps of the viral life cycle, thus representing a top drug target. [3]